ONVO News and Press, Organovo Holdings Inc.

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier ne...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April ...

2025-04-02 08:51:01 ET More on Organovo Holdings Organovo gets upfront payments following sale of its FXR Program to Lilly Organovo announces reverse stock split; shares fall Seeking Alpha’s Quant Rating on Organovo Holdings Read the full article on ...

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary u...

2025-03-27 09:25:16 ET More on Eli Lilly, Organovo Holdings, etc. Eli Lilly: Growth With Higher Margins Eli Lilly: A Safe Harbor Amid Market Volatility Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript) M...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business upda...

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successfu...

2025-03-19 08:14:09 ET More on Organovo Holdings Eli Lilly to acquire Organovo’s FXR program Seeking Alpha’s Quant Rating on Organovo Holdings Historical earnings data for Organovo Holdings Financial information for Organovo Holdings R...

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and o...

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “E...